Summary:
- Jocasta Neuroscience, Inc. secured $35M in Series A financing to support the development of its lead compound, JN-0413, targeting cognitive decline associated with neurodegenerative-induced dementia.
- The funding round was led by True Ventures and included investments from other key players in the industry.
- CEO Albert Agro is leading the preclinical stage biotech company in advancing their proprietary formulation of a-Klotho protein for clinical trials in patients with dementia and cognitive decline.
Article:
Jocasta Neuroscience Secures $35M in Series A Funding for Cognitive Decline Research
Jocasta Neuroscience, Inc., a Scottsdale-based company in the preclinical stage, has successfully raised $35M in Series A financing. The funding will be pivotal in advancing the development of their lead compound, JN-0413, which aims to address cognitive decline associated with neurodegenerative-induced dementia.
The funding round was spearheaded by True Ventures, with contributions from Moore Strategic Ventures, SC8 Investments, Glentura, Yagan Family Foundation, and other notable investors in the industry. This strong support demonstrates the confidence in Jocasta Neuroscience’s mission and the potential impact of their research in the field of cognitive health.
Under the leadership of CEO Albert Agro, Jocasta Neuroscience is focused on developing a proprietary formulation of a-Klotho protein (JN-0413) to manage cognitive decline. Their research has shown promising results, highlighting the critical role of a-Klotho in both health and disease. From human genetics studies to cognitive enhancement in animal models, the data supporting the advancement of JN-0413 into clinical trials is compelling.
With an IND submission scheduled for Q4 2026, Jocasta Neuroscience is on track to make significant strides in the treatment of dementia and cognitive decline. The company’s dedication to innovation and their commitment to improving the lives of those affected by neurodegenerative diseases make them a key player to watch in the biotech industry.
In conclusion, the recent funding success of Jocasta Neuroscience marks a significant milestone in their journey towards developing effective treatments for cognitive decline. With a strong team and promising research, they are poised to make a meaningful impact in the field of neurodegenerative diseases.
